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Pericytes (PC) are mural cells that surround endothelial cells in small blood vessels. 
PC have traditionally been credited with structural functions, being essential for vessel 
maturation and stabilization. However, an accumulating body of evidence suggests that 
PC also display immune properties. They can respond to a series of pro-inflammatory 
stimuli and are able to sense different types of danger due to their expression of 
functional pattern-recognition receptors, contributing to the onset of innate immune 
responses. In this context, PC not only secrete a variety of chemokines but also 
overexpress adhesion molecules such as ICAM-1 and VCAM-1 involved in the control 
of immune cell trafficking across vessel walls. In addition to their role in innate immunity, 
PC are involved in adaptive immunity. It has been reported that interaction with PC 
anergizes T cells, which is attributed, at least in part, to the expression of PD-L1. 
As components of the tumor microenvironment, PC can also modulate the antitumor 
immune response. However, their role is complex, and further studies will be required 
to better understand the crosstalk of PC with immune cells in order to consider them 
as potential therapeutic targets. In any case, PC will be looked at with new eyes by 
immunologists from now on.
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iNTRODUCTiON
Pericytes (PC) were first described 145 years ago by Carl Joseph Eberth and “rediscovered” 2 years 
later by Charles-Marie Benjamin Rouget. They were given their current name by Karl Wilhelm 
Zimmermann in 1923 (1), due to their location wrapping around capillaries and postcapillary ven-
ules. However, they remain elusive cells with intriguing properties that have only recently attracted 
the attention of numerous researchers. This is due, in part, to the relatively low numbers of PC in 
most tissues (with the CNS being an exception) and exacerbated by the absence of truly unique 
markers, increasing the difficulty of isolating pure primary PC. In fact, cultured human PC have not 
been readily available until a few years ago, which explains the sparse data available on PC compared 
to the far more characterized endothelial cells (EC) (2).
To make the picture more complex, PC are heterogeneous in terms of phenotype, distribution, 
and embryonic origin. Markers used to identify PC include PDGF receptor-β (PDGFR-β), nerve-
glial antigen-2/chondroitin sulfate proteoglycan 4 (NG2), the regulator of G-protein signaling-5 
(RGS5), α-smooth muscle actin (αSMA), desmin, aminopeptidase N (CD13), endoglin (CD105), 
the adhesion molecule CD146, and many others (3). However, not all PC express every single 
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marker; their expression is dynamic and varies between organs, 
developmental stages, activation/maturation state, and across 
individual microvascular networks. Neither are most of these 
markers found exclusively on PC (4). Moreover, it has been 
suggested that PC and vascular smooth muscle cells (VSMC) 
that surround larger vessels represent phenotypic variants of a 
continuous population of mural cells (5).
Initially, light and electron microscopy were the only 
techniques able to visualize them, and PC distinct from other 
perivascular cells could not be identified precisely. However, 
definition of PC by criteria that requires ultrastructural analysis 
for identification is not practical (6). Currently, at least two 
markers (positive reactivity to both PDGFR-β and NG2 being 
widely accepted) as well as morphology and cell location (in 
close contact with EC, embedded in the same basement mem-
brane) are required to unequivocally distinguish PC from other 
mesenchymal cells (7). The use of transgenic mouse models 
fluorescently labeling PC [e.g., NG2-dsRed (8), the inducible 
NG2-CreERT2-eGFP (9), αSMA-GFP or αSMA-mCherry (10), 
and the double-transgenic nestin-GFP/NG2-DsRed mouse 
(11)] may be essential for studying the fate of PC under dif-
ferent conditions.
Pericytes have a well-known role in angiogenesis and vas-
cular homeostasis, participating in guidance of the endothelial 
tip cells and vessel maturation and stabilization (12, 13). The 
initial stage of angiogenesis begins with PC–EC detachment and 
basement membrane degradation, followed by EC migration 
and proliferation and subsequent EC tube assembly and vessel 
stabilization by newly recruited PC (14). Recent studies support 
the notion that PC-mediated signaling may also be crucial for 
the growth phase of angiogenesis: PC may act as pioneers in 
the angiogenic sprout, creating pathways for guiding migrating 
EC (15).
Several signaling pathways have been characterized in 
the PC–EC crosstalk, including PDGF-B/PDGFR-β, TGF-β/
ALK1/5, angiopoietin-1/Tie-2, and Jag1/Notch3 (16). Their role 
in the regulation of flow rate is more controversial (17), although 
discrepancies may be due to the lack of a clear definition of PC 
subpopulations (18). But PC not only provide structural support 
to EC, as it was classically assumed. Recently, several works have 
endowed PC with unexpected mesenchymal stem cell (MSC)-like 
properties. PC can express MSC markers and behave like MSC 
both in vitro and in vivo. Conversely, MSC have been attributed a 
perivascular origin (19) and can exhibit a PC-like behavior (20). 
They have also a role in cancer biology, where they participate 
in tumor angiogenesis and metastasis (21). However, PC have 
received far less credit as being immune regulators.
Rapidly expanding insights into their physiological and patho-
logical functions have attracted the attention of many research 
groups. Beyond the field of angiogenesis research, PC have been 
mainly in the focus of neuroscientists, because of their central 
role in blood–brain barrier maintenance and the implication of 
their loss in diabetic retinopathy (13, 22). The PC “avatars” in the 
liver (hepatic stellate cells) and kidney (mesangial cells) have also 
received attention due to their role in fibrosis. Here, we aim to 
make these elusive cells mostly appealing for the community of 
immunologists.
ARe PeRiCYTeS NON-PROFeSSiONAL 
MACROPHAGe-LiKe CeLLS?
Pioneering studies suggested that PC do not represent 
mere bystanders in the inflammatory response, but display 
 macrophage-like, non-professional antigen-presenting cell 
(APC)  characteristics, suggesting possible participation in 
immune responses (23–25). In 1999, a comprehensive review 
summarized the knowledge about the potential role of brain 
PC (mainly of rodent origin) as macrophage-like cells (26). 
PC macrophage markers reported by different groups included 
CD4, major histocompatibility complex (MHC) class II 
molecules, CD45 (leukocyte-common antigen), Fc receptors, 
scavenger receptors, CD11b (alpha chain of the integrin 
Mac-1/CR3), the pan-macrophage marker CD68 (ED1), and 
the M2-polarized-specific marker CD163 (ED2) (23, 27–29). 
Among the macrophage-like properties of PC, pinocytosis 
and phagocytosis were documented. In this way, they could 
contribute to the removal of toxic cellular by products from 
the microcirculation. Very early in  vivo studies (30, 31) had 
demonstrated accumulation of tracer particles in PC after 
systemic administration, which is suggestive of their phagocytic 
ability. Much later, phagocytic activity was confirmed in cultured 
primary rat PC using opsonized beads (23).
Macrophages are classical APC, which, in addition to MHC 
class II molecules, express co-stimulatory molecules such as CD80 
and CD86. Non-professional APC that only express MHC class 
I molecules may function as APC after induction of MHC class 
II molecules expression by interferon-gamma (IFN-γ). Indeed, 
brain PC treated with IFN-γ expressed MHC class II molecules 
and acquired the capacity to present antigen to primed syngeneic 
T lymphocytes from rats immunized with myelin basic protein 
or ovalbumin (32). T cell proliferation was antigen specific and 
MHC class II dependent because an irrelevant antigen failed to 
induce incorporation of labeled thymidine and non-activated PC 
did not support it. The PC proliferative response was comparable 
to that produced by syngeneic APC and was dose and ratio 
dependent. Previously, cells referred to as smooth muscle/PC 
have been shown to selectively induce the Ag-specific activation 
of different Th1 clones, reflected by cell proliferation and produc-
tion of IL-2 (33).
However, some of these pioneering findings have been ques-
tioned as clear-cut identification of PC was not provided, and the 
results might rather be attributed to perivascular macrophages 
(34). Controversy had already appeared in early studies using 
transmission electron microscopy that distinguished perivascu-
lar cells, which ingested carbon particles, from PC, which did not. 
The results of this study suggested that at least some perivascular 
cells remain distinct from PC (35).
More recent studies have reported that isolated porcine brain 
PC do not express MHC class II molecules under basal conditions, 
but IFN-γ can induce its mRNA (36) and protein expression (37). 
In a mouse model of PDGFR-β gain-of-function, activation of 
brain PC prompted the expression of immunoregulatory genes, 
including MHC class II molecules, Fcγ receptors and proteosome 
subunits as PSME1 (38). IFN-γ also upregulated CD68 mRNA, 
and both IFN-γ and TNF-α increased the phagocytosis of latex 
TAbLe 1 | Cytokines, chemokines, and adhesion molecules expressed by 
pericytes in response to pro-inflammatory stimuli.
Stimuli Cell source Reference
Cytokine/chemokine
CCL2/MCP-1 LPS HBP (45)
TNF-α, IL-1β, LPS HBP (47)
LPS, TNF-α HPP (49)
TNF-α RBP (51)
TNF-α, IL-1β HRP (46)
IL-1β HBP (48)
IL-1β HBP (39)
LPS, IFN-γ HBP (53)
CCL3/MIP-1α LPS MBP (55)
TNF-α RBP (51)
TNF-α, IL-1β HRP (46)
CCL4 LPS MBP (55)
CCL5/RANTES TNF-α RBP (51)
HCMV HBP (54)
TNF-α, IL-1β HRP (46)
CCL11/eotaxin LPS MBP (55)
TNF-α HRP (60)
CXCL1/GROα/KC LPS HBP (45)
LPS, TNF-α HPP (49)
TNF-α MMP (61)
TNF-α RBP (51)
CXCL10/IP-10 TNF-α, IL-1β, LPS HBP (47)
TNF-α RBP (51)
IFN-γ HBP (37)
CXCL11 HCMV HBP (54)
CX3CL1 IL-1α HBP (39)
G-CSF LPS MBP (55)
TNF-α, IL-1β HRP (46)
TNF-α HBP (52)
GM-CSF LPS MBP (55)
TNF-α, IL-1β HRP (46)
IFN-γ LPS MBP (55)
IL-1α TNF-α RBP (51)
IL-1β LPS RLP (60)
High glucose BRP (62)
IL-2 TNF-α RBP (51)
IL5 TNF-α RBP (51)
IL-6 LPS HBP (45)
TNF-α RBP (51)
HCMV HBP (54)
IL-17 HPP (43)
IL-6 (Cont.) TNF-α, IL-1β HRP (46)
IL-1β HBP (48)
LPS MBP (50)
TNF-α HBP (52)
TGF-β1 HBP (39)
IL8/CXCL8 LPS, HMGB1 HBP (45)
LPS, TNF-α HPP (49)
HCMV HBP (54)
TNF-α, IL-1β HRP (46)
LPS, TNF-α, IL-1β PBP (56)
IL-1β HPP (57)
C12-iE-DAP HBP (58)
IL-1β HBP (48)
TNF-α HBP (52)
IL-1β HBP (39)
TNF-α HPP (59)
IL-17 HPP (43)
IL-10 LPS MBP (55)
IL-12 LPS MBP (55)
IL-13 LPS MBP (55)
IL-17 TNF-α RBP (51)
(Continued)
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beads in SMA+, desmin+, CD90+, and NG2+ pig brain PC (36). On 
the other hand, PC phagocytic ability was attenuated by  TGF-β1, 
possibly through downregulation of the scavenger receptors 
CD36, CD47, and CD68 (39).
However, in a recent work, pretreatment with different stimuli, 
including IFN-γ, failed to induce an APC-like phenotype in 
human PC from various origins (placenta, brain, and CD146+, 
CD105+ pluripotent stem cell-derived). PC constitutively 
expressed MHC class I but not MHC class II or the co-stimulatory 
molecules CD80 or CD86. As previously described, incubation of 
cultured PC with IFN-γ induced the expression of MHC class II 
by all types of PC. On the contrary, IFN-γ did not stimulate the 
expression of CD80 or CD86 and did not significantly affect the 
proliferation of CFSE-labeled CD4+ T cells in comparison with 
untreated PC (40).
In summary, more studies are needed to establish the role of 
PC as macrophage-like cells, once unequivocal identification is 
warranted.
PeRiCYTe ReSPONSe TO  
PRO-iNFLAMMATORY CUeS
It is well known that activated EC can secrete a plethora of 
cytokines and chemokines that are important in potentiating 
inflammatory responses (41). Numerous in  vitro studies have 
shown that EC secrete CXC (CXCL1, CXCL2, CXCL8, CXCL9, 
CXCL10, CXCL11), CC (CCL2, CCL3, CCL5, CCL7), and CX3C 
chemokines in response to various inflammatory stimuli. These 
studies correlate with in  vivo studies demonstrating a role for 
these endothelial-derived chemokines in mediating leukocyte 
recruitment during various inflammatory conditions (42).
Similarly, PC of multiple origins have been reported to 
secrete a plethora of chemokines and cytokines in response 
to pro-inflammatory stimuli released by professional innate 
immune cells, mainly TNF-α, IL-1β, and IFN-γ (Table  1). 
Interestingly, human PC have recently been shown to be 
much more responsive than human EC to IL-17 stimulation 
in producing pro-inflammatory molecules (43). Commonly 
upregulated pro-inflammatory factors include: CXCL8, IL-6, 
CCL2, CCL3, CCL5, CXCL1, and CXCL10. These cytokines 
and chemokines may be important in potentiating inflamma-
tory responses by inducing cytokine secretion by other cells and 
recruiting immune cells to the site of inflammation. CXCL8 and 
CXCL1 bind to both receptors CXCR1 and CXCR2, expressed 
mainly by neutrophils. Of note, IL-17-stimulated PC not only 
overexpressed CXCL8 but also induced neutrophil synthesis of 
TNF-α, IL-1α, IL-1β, and CXCL8 (43). CCR2, the CCL2 recep-
tor, is expressed mainly by monocytes. CXCR3 is the CXCL10 
receptor, involved in Th1, CD8, and NK cell trafficking. CCL3 
and CCL5 bind to CCR1 and CCR5 and modulate monocyte, 
macrophage, Th1, CD8, and NK cell migration (44). Therefore, 
all these cell types may be lured by activated PC to a site of 
inflammation (Figure 1).
Chemokines produced by PC also have a key role in inflamma-
tion-associated angiogenesis. CXCL1 and CXCL8 belong to the 
CXC chemokine subgroup with glutamic acid–leucine–arginine 
(the ELR motif) immediately proximal to the CXC sequence, 
FiGURe 1 | The schematic drawing describes the close spatial 
relationship and the complex interactions between pericytes and 
different cells of the innate and adaptive immune system.
Stimuli Cell source Reference
MIF LPS, TNF-α HPP (49)
TNF-α LPS, TNF-α MBP (55)
High glucose BRP (62)
Adhesion molecule
ICAM-1 TNF-α, IFN-γ RBP (32)
LPS HBP (45)
TNF-α MMP (61)
TNF-α, LPS HPP (49)
TNF-α, IFN-γ HBP (63)
IL-1β HPP (57)
High glucose BRP (62)
IL-1β HBP (48)
TNF-α HPP (59)
TNF-α, IFN-γ HPP (64)
LPS, IFN-γ HBP (53)
VCAM-1 TNF-α RBP (32)
LPS HBP (45)
TNF-α HBP (63)
TNF-α HPP (59)
BRP, bovine retinal pericytes; HBP, human brain pericytes; HCMV, human 
cytomegalovirus; HPP, human placental pericytes; HRP, human retinal pericytes;  
MBP, mouse brain pericytes; MMP, mouse muscle pericytes; PBP, pig brain pericytes; 
RBP, rat brain pericytes; RLP, rat lung pericytes.
TAbLe 1 | Continued
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which promote the migration and proliferation of CXCR1- and 
CXCR2-expressing EC (65). In addition to the ELR+ CXC 
chemokine family, CCL2 is the best known CC chemokine media-
tor of neovascularization. This pattern of chemokine production 
may shed new light on PC–EC interactions, suggesting a dual 
role for PC according to their activation status. In physiologi-
cal conditions, PC are necessary to maintain a quiescent stable 
endothelium; however, activated PC could act as drivers of 
angiogenesis during inflammatory processes.
Increased vascular permeability is a hallmark of inflammation, 
and PC may play a role in this response. It has been shown that 
TNF-α, IL-1β, and IFN-γ promote the expression of inducible 
nitric oxide synthase (iNOS) by porcine (36) and rat (51) brain 
PC. The generation of NO by PC can act in both an autocrine and 
paracrine manner as a relaxing factor, which leads to vasodila-
tion. In addition, an iNOS-independent pathway by which lung 
PC contractility is regulated by lipopolysaccharide (LPS) has 
been suggested (66). VEGF modifies the contractile response of 
lung PC, and this mechanism may play a role in the increased 
permeability demonstrated in inflammatory conditions (67). PC 
also upregulate cyclooxygenase-2 (COX-2), responsible for pro-
duction of inflammatory prostaglandins, and generate reactive 
oxygen and nitrogen species after the stimulation with TNF-α, 
IL-1β, or IFN-γ (36). In another study, microarray analysis 
of PDGFRβ+, SMA+ human brain PC treated with IFN-γ and 
IL-1β revealed widespread changes in gene expression including 
upregulation of interleukins, chemokines, adhesion molecules, 
PTGS2/COX2, and SOD2 (47). Increased superoxide dismutase 
expression by PC could confer tolerance to oxidative stress in the 
inflammatory context.
Aside from participating in the onset of inflammatory 
responses, autolimiting mechanisms have also been identified 
in PC. The transcription factor C/EBPδ is induced in a concen-
tration- and time-dependent fashion in PDGFRβ+, SMA+, and 
NG2+ human brain PC by IL-1β, limiting PC production of CCL2 
and thereby preventing further inflammatory responses (48).
All these works support the potential of PC to take part in 
immunological responses under inflammatory conditions (36). 
However, their role is complex: Pdgfrβ+/− mice showed an age-
dependent progressive loss of PC coverage in the brain associated 
with neutrophil infiltration and expression of several inflamma-
tory factors (TNF-α, IL-1β, IL-6, CCL2) and ICAM-1 (68).
PC AS SeNTiNeLS OF THe iNNATe 
iMMUNiTY
Several classes of receptors, collectively termed pattern- 
recognition receptors (PRR) are responsible for sensing 
 microorganisms and endogenous molecules released during 
cell injury. These germ line-encoded PRR recognize conserved 
pathogen-associated molecular patterns (PAMPs) and danger-
associated molecular patterns (DAMP). Five families of PRR 
have been identified in mammals, of which toll-like receptors 
(TLRs) and NOD-like receptors (NLRs) are the most studied and 
characterized (69). Beyond the passive role of PC in the amplifica-
tion of inflammatory responses above described, expression of 
functional PRR suggests that brain PC may directly contribute to 
the onset of innate immune responses.
Human EC are known to express several TLRs, whereas 
inflamed endothelium has significant upregulation of TLR2 
(receptor for di/triacyl lipopeptides) and TLR4 (LPS recep-
tor) (70, 71). However, expression of these receptors in PC 
has been scarcely addressed. In a series of pioneering works 
by Edelman et al., the authors demonstrated TLR4 upregula-
tion (72), increased vessel permeability (73), and production 
of IL-1β (60) in rat lung PC treated with LPS, suggesting an 
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active role of PC in inflammation. Subsequently, the release of 
NO and several cytokines and chemokines by SMA+, CD13+ 
mouse brain vascular PC in response to LPS was reported (55). 
More recently, we have documented the expression of TLR4 by 
human brain PC and their responsiveness to both LPS and the 
endogenous ligand HMGB1 (45). In this study, the transcrip-
tional profile of LPS-treated PC was characterized using DNA 
microarrays. Shortly after, Jansson et al. confirmed the ability 
of human brain PC to respond to different pro-inflammatory 
stimuli, including LPS (47).
Pattern-recognition receptors signaling in innate immune 
cells results in the production of a variety of pro-inflammatory 
molecules. In LPS-treated human brain PC, six genes were found 
to be upregulated more than 15-fold: CXCL10, CCL20, CXCL8, 
CXCL1, IL-6, and CCL2 (45) (Table 1). Interestingly, these data 
corroborated a different capacity in synthesis of pro-inflammatory 
factors between vascular cells and leukocytes in response to 
PAMPs or analogs. It had been described that vascular VSMC 
and EC cells produce 10- to 100-fold more IL-6, CXCL8, and 
CXCL10, whereas leukocytes are nearly exclusive producers of 
IFN-γ and TNF-α, at least in humans (74). Intriguingly, LPS 
induces in human coronary artery EC mRNA expression of 
IL-1α, IL-1β, and TNF-α, but no release of the proteins (75). 
Similarly, a significant upregulation of IL-1α and IL-1β mRNA 
in human brain PC was observed, but expression at protein 
level could not be detected (45). The profiles of cytokines and 
chemokines released by human and mouse brain PC in response 
to LPS also differ considerably, supporting major species differ-
ences in vascular cell immunological functions, as highlighted by 
Pober and Tellides (76). Indeed, it is controversial how closely 
the gene-expression patterns in mouse models recapitulate those 
in human inflammatory conditions (77, 78).
A recent report described that LPS-induced secretion of certain 
inflammatory cytokines/chemokines such as CCL2 and CXCL1 
by HUVEC was inhibited by the axon guidance molecule Slit2 and 
its receptor Robo4 pathway (79). Previously, it had been shown 
that Robo4-dependent Slit2 signaling reduces the endothelial 
hyperpermeability induced by LPS in vivo (80). Interestingly, we 
described the expression of Robo4 in human brain PC and their 
response to Slit2 (81), which inhibited spontaneous and PDGF-
B-induced migration of PC. It remains to be addressed whether 
the Slit2-Robo4 axis also modulates the inflammatory response 
in human brain PC.
NOD1 and NOD2, the prototypical members of the NLR 
family of PRR, mediate the cytoplasmic recognition of pepti-
doglycan (PGN) fragments (82). NOD1 is expressed in a variety 
of cell types of both hematopoietic and non-hematopoietic 
origin, including EC, where it has been shown to be critical 
in sensing pathogens (83) and mediating vascular inflamma-
tion (84). The expression of these PRR in PC had not been 
addressed, but a recent report by our group showed that NOD1 
is functionally expressed by PC, whereas NOD2 expression 
is barely detectable. The NOD1 agonist C12-iE-DAP induced 
IL-6 and CXCL8 gene expression by PC as well as their release 
into culture supernatant. Moreover, the synergistic effect of 
NOD1 and TLR4 agonists on the induction of CXCL8 was 
demonstrated (58).
Recently, it has been reported that human brain primary PC 
cultures contain at least two functionally distinct CD73+ cell 
types: one being the more proliferative, CD90+ (Thy-1) cells, 
and CD90− cells, which show a greater inflammatory response 
to LPS and IFN-γ stimulation (53). In fact, the primary human 
brain PC we used to characterize the response to LPS, HMGB1, 
and C12-iE-DAP expressed canonical high levels of PDGFR-β, 
NG2, CD13, CD73, and CD105 but unexpectedly lacked CD90, 
as assessed by flow cytometry (81). It will be interesting to learn 
more about the biological significance of CD90 and the discrete 
roles of these PC subpopulations in physiological and pathologi-
cal conditions.
PeRiCYTe CONTROL OF iMMUNe 
CeLL TRAFFiCKiNG
Leukocyte trafficking to target tissues is orchestrated by adhesion 
molecules and chemokines that stabilize dynamic interactions 
between immune cells and EC. While PC have long been dis-
regarded as players in this process, accumulating evidence have 
shed light on the significance of these cells as regulators of leuko-
cyte recruitment to inflammation sites. This new understanding 
has been enabled by advances in microscopy techniques and the 
generation of genetically fluorescent animal models. Intravital 
imaging studies have revealed the events following leukocyte 
transendothelial migration in  vivo: to fully exit venular walls, 
infiltrating cells must breach the basement membrane and cross 
the PC sheath to enter the perivascular space, which creates a 
special milieu that controls the behavior and fate of infiltrated 
immune cells (85, 86).
Recent works have demonstrated that PC facilitate neutrophil 
transmigration in a model of TNF-α- or IL-1β-stimulated mouse 
cremaster muscle in vivo (61, 87). Namely, PC were observed to 
provide a substrate for neutrophils creeping along their processes 
(“abluminal crawling”) to gaps between adjacent PC which 
are enlarged in inflamed tissues and used as exit points. This 
response was mediated through the interaction of PC-expressed 
ICAM-1 with neutrophil Mac-1 and LFA-1 (61). Previous stud-
ies by the same group had shown that these gaps were aligned 
with regions of low densities of the extracellular matrix proteins 
collagen IV and laminin 10 in the basement membrane (low-
expression regions, LERs) (88–90). PC relaxation rather than 
contraction contributes to the opening of the gaps between PC 
and to the widening and thinning of LERs, facilitating neutrophil 
extravasation (87).
Moreover, capillary and arteriolar NG2+ PC can “instruct” 
extravasating neutrophils and monocytes with migratory 
cues after exiting through postcapillary venules covered 
by NG2− PC (49). In response to inflammatory mediators, 
NG2+ PC upregulated expression of ICAM-1 and released 
the chemoattractant MIF, which directed interstitial leukocyte 
trafficking. In this setting, PC-driven migration of monocytes 
was mediated mainly by MIF and CCL2, whereas neutrophil 
migration involved MIF and CXCL8. These interactions with 
the abluminal face of NG2+ PC were crucial for the efficient 
navigation of cells of the innate immune system and enhanced 
TAbLe 2 | Modulation of T cell activation and antitumoral immune response by pericytes.
Pericyte type/origin In vitro effect Tumor model In vivo effect Reference
HBP T cell adhesion, VCAM-mediated N/A N/A (63)
HPP T cell anergy N/A N/A (64)
HRP, MRP T cell inhibition, PDL1/
IL-10-mediated
N/A N/A (93)
HPSC-derived PC, HBP, HPP T cell hyporesponsivenes, induction 
of Tregs, PD-L1/TGFβ-mediated
N/A N/A (40)
C3H10T1/2-in vitro differentiated, 
tumor-conditioned PC; B16  
tumor-derived PC
CD4+ T cell anergy, RGS5- and 
IL-6-dependent
B16 mouse melanoma N/A (94)
HBP T cell anergy, PGE2-, NO-, HGF, 
TGFβ-mediated
Human malignant glioma N/A (95)
PDGF-B ret/ret mouse model 
(pericyte-deficient)
N/A B16 melanoma, LLC mouse  
lung cancer
Recruitment of T-cell suppressive 
MDSC, IL-6 mediated. Increased 
tumor growth and metastasis
(96)
Rgs5−/− mouse model N/A RIP1-Tag5  
(insulinoma) × Rgs5−/− mouse 
model
Vascular normalization and 
enhanced infiltration of CD8+ T cells. 
Increased survival
(97)
FVB/N mice N/A NT-2 mouse breast cancer Increased infiltration of CD8+ cells 
after vaccination against pericyte 
antigens. Delayed tumor growth
(98)
C57BL/6, HDD (HLA-A2 
transgenic) mice
N/A MC38 mouse colon carcinoma, 
B16 melanoma
Increased infiltration of CD8+ cells 
after vaccination against pericyte 
antigens. Tumor eradication
(99)
SCID, C57BL/6, C57BL/6 
IL-33−/− mice. Isolated LMP
PDGF-BB-induced IL-33 expression 
in LMP. Increased migration of  
IL-33-primed macrophages
pdgfb-shRNA A431 human 
epidermoid carcinoma,  
pdgfb-overexpressing murine 
T241 fibrosarcoma and LLC cells
Recruitment of TAM, IL-33 
mediated. Metastasis promotion
(100)
HBP, human brain pericytes; HPP, human placental pericytes; HPSC, human pluripotent stem cells; HRP, human retinal pericytes; LLC, Lewis lung carcinoma; LMP, lung mouse 
pericytes; MDSC, myeloid-derived suppressor cells; MRP, mouse retinal pericytes; TAM, tumor-associated macrophages.
6
Navarro et al. Pericytes as Immune Modulators
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 480
the ability of the latter cells to screen the interstitial space for 
damaged tissue and to execute their effector functions at foci 
of sterile inflammation.
Significantly, the in  vitro coculture of human umbilical 
vein EC and CD90+, NG2+ human placental PC indicated that 
transendothelial migration itself, which increases neutrophil 
Mac-1 surface expression, can prime neutrophils for enhanced 
interactions with PC (57). Another in  vitro model showed 
that porcine brain PC are able to chemoattract neutrophils 
by CXCL8 after stimulation with LPS, TNF-α, or IL-1β (56). 
Remarkably, LPS-treated human brain PC showed a strong 
increase in the expression of both ICAM-1 and VCAM-1 which 
promoted a significant increase in adhesion of peripheral blood 
lymphocytes to human brain PC (45). Notably, VCAM-1/
VLA-4 interaction was proposed more than 20 years ago as a 
mechanism mediating T cell–human brain PC crosstalk (63). 
In a much more recent study, PC have been shown to control 
mature T cell transmigration across the endothelium from the 
thymus into circulation (91).
Collectively, these findings showed that interactions of PC 
with different types of leukocytes modulate their trafficking 
through vessel walls. The impact of such interactions on the 
phenotype and activation state of immune cells requires further 
investigations.
MODULATiON OF ADAPTive iMMUNe 
ReSPONSeS bY PC
If PC can regulate T cell trafficking, it is obvious that they are also 
positioned to modulate T cell activation (76) (Table 2). Human 
EC have been considered amateur APC, since they lack expres-
sion of key co-stimulatory molecules such as CD80 and CD86, 
as it has been reported for PC. But PC also display higher levels 
of PD-L1 and PD-L2, ligands for the inhibitory immune check-
point molecule PD1 expressed by activated T cells. In agreement 
with these observations, IFN-γ-treated MHC class II+ human 
placental PC, unlike EC, cannot stimulate resting allogeneic CD4 
T cell proliferation or cytokine production. Instead, coculture 
with PC renders T cells anergic (64). These placental PC express 
characteristic markers NG2, CD90, CD146, and SMA. Like PC, 
the ontogenetically related MSC have been reported to inhibit 
T cell proliferation (92).
Retinal PC also have immunosuppressive properties, and 
coculture with activated T cells decreased proliferation and 
IFN-γ and TNF-α production in a dose-dependent manner (93). 
Both cell–cell contact and soluble factors are involved in retinal 
PC-mediated T cell inhibition, since it was decreased by the 
addition of blocking anti-PD-L1 and anti-IL-10 antibodies, and 
in transwell experiments. Interestingly, retinal PC protected EC 
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from T cell-induced death, suggesting that their loss under hyper-
glycemic conditions favors retinal inflammation and contributes 
to the pathogenesis of diabetic retinopathy.
Characterization of different subsets of lymph node stromal 
cells (LNSC) identified a novel gp38- and CD31-double-negative 
population. These cells expressed high levels of autoimmune 
regulator (AIRE) and showed a strong response to inflammation 
by upregulating peripheral tissue-restricted antigen expression. 
Of interest, double-negative LNSC upregulated PD-L1 in PolyI:C-
treated mice, suggesting a potential contribution to shaping the 
T cell repertoire and peripheral tolerance (101). In a subsequent 
study, transcriptional profiling of LNSC analyzing each subset’s 
expression signature identified double-negative LNSC as PC able 
to respond to inflammatory or infectious triggers (102).
In another study, human brain or placental PC and PC derived 
from human pluripotent stem cells (hPSC) mediated a significant 
increase in the frequency of allogeneic CD25 high FoxP3+ 
regulatory T cells (Tregs) when cocultured with non-activated 
peripheral blood T cells. PD-L1/2 expression and secretion of 
TGF-β by hPSC PC directly regulated generation of Tregs favor-
ing allostimulation of Tregs over T cell activation, suggesting 
that hPSC PC could be applied to allogeneic cell therapy in the 
clinic, not only without provoking immediate immune responses 
but also actively modulating suppressive immunity (40).
In summary, PC are not only players in innate immunity and 
inflammation but they can also participate, at least under certain 
circumstances, in adaptive immunity.
iMMUNe ReGULATiON bY PC iN THe 
TUMOR MiCROeNviRONMeNT
The role of stromal cells in the tumor microenvironment (TME) 
has attracted great interest, and PC are bona fide components of 
the TME, although its coverage of tumor microvasculature is 
controversial (103–105). Undoubtedly, the immunomodulatory 
properties of PC may have an impact in the context of antitumor 
immune responses. Along with PD-L1 and PD-L2 expression, PC 
from normal human brain and human malignant glioma (both 
PDGFRβ+, desmin+, SMA+, and NG2+) have been shown to secrete 
various factors with immunosuppressive properties, such as NO, 
PGE2, and TGF-β (95). Not surprisingly, previous in vitro results 
have a correlation with the antitumor immune response in vivo. 
PC derived from subcutaneously implanted B16 or CT26 tumors 
expressed, unlike their normal counterparts, MHC class II and 
CD80 molecules (94). In this work, PD-L1 expression was upregu-
lated in normal PC after culture in tumor-conditioned media. 
Tumor-derived PC, but not normal PC, negatively influence CD4+ 
T cell activation and proliferation in vitro, and promote anergy in 
OVA-specific cells in culture. This immunoregulatory capacity was 
dependent on TME-induced RGS5 expression and IL-6, and could 
help tumors to evade immune responses (94). Similarly, PC isolated 
from human malignant glioma were equally capable of suppressing 
allogeneic or mitogen-activated T cell responses in vitro through the 
production of PGE2, TGF-β, and NO. Moreover, CD90+ PDGFR-β+ 
perivascular cells accumulated in human gliomas with increasing 
degree of malignancy and negatively correlated with the presence of 
blood vessel-associated leukocytes and CD8+ T cells (95).
In line with these findings, PC targeting has shown antitumor 
effects in vivo. A study with the RIP1-Tag5 mouse model of pan-
creatic carcinoma showed that deletion of the Rgs5 gene induced 
changes in the vasculature and enhanced infiltration of CD8+ 
T cells in tumors after adoptive transfer. As a consequence, the 
immune-mediated tumor rejection was exacerbated, resulting in 
improved survival of tumor-bearing mice (97). Notably, RGS5 is 
also overexpressed in tumor PC in this model, similar to what has 
been documented for several human tumors, including kidney, 
liver, and head and neck cancers (97, 106).
Tumor PC have also been targeted using vaccination 
approaches. In a breast carcinoma model, immunization with a 
Listeria monocytogenes-based vaccine against NG2 was shown to 
promote tumor infiltration of CD8+ T cells and tumor regression 
(98). Indeed, vaccination with peptides derived from PDGFR-β 
and RGS5 were also effective in preventing HLA-A2− colon 
carcinoma (MC38) establishment or resulted in the regression 
of tumors in HLA-A2 transgenic mice (99). Effective vaccination 
resulted in profound infiltration of tumor lesions by CD8+ cells 
and supported the idea that targeting tumor PC can alleviate local 
immunosuppression.
However, the role of PC in TME is complex, as they may 
contribute to different cancer hallmarks beyond immune eva-
sion (107), and consequently their role as potential targets in 
cancer immunotherapy approaches should be carefully evaluated. 
In the PDGF-B (ret/ret) mouse model, PC deficiency produced 
defective tumor vasculature, resulting in a more hypoxic microen-
vironment. Hypoxia promoted IL-6 upregulation in the malignant 
cells and increased transmigration of myeloid-derived suppressor 
cells (MDSC) in experimentally induced tumors. MDSC accu-
mulation in tumors led to increases in tumor growth, whereas 
restoring the PC coverage in tumors abrogated the increased 
MDSC trafficking to PC-deficient tumors (96). Though, another 
study reported that IL-33 produced by PDGF-B-stimulated PC 
promoted metastasis through recruitment of tumor-associated 
macrophages in several human and mouse graft tumor models 
(100). Further extensive studies will be required to understand 
the crosstalk of PC with immune cells different from T cells.
CONCLUSiON AND PeRSPeCTiveS
Pericytes have demonstrably been shown to possess an immuno-
logical role beyond their structural role in the microvasculature. 
PC can respond to a series of pro-inflammatory stimuli and are 
also able to discriminate between several types of danger and 
mount a complex secretory response: upon PAMP engagement, 
PRR trigger intracellular signaling cascades ultimately culminat-
ing in the expression of a variety of pro-inflammatory molecules. 
At the same time, PC overexpress adhesion molecules that guide 
and instruct innate immune cells after transendothelial migra-
tion. Moreover, PC are implicated in shaping adaptive immunity, 
with several studies that point to an immunosuppressive role. 
This role may have an impact on the antitumor immune response, 
since PC are constituents of the TME. A better understand-
ing of the mechanisms by which PC communicate with their 
neighboring cells and modulate immune responses in tumors 
can be expected to yield exciting new insights as well as help 
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in the development of new therapeutic targets with important 
implications for cancer immunotherapy.
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